Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression >= 50%-MedSci.cn

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression >= 50%

Metro, G; Banna, GL; Signorelli, D; Gili, A; Galetta, D; Galli, G; Economopoulou, P; Roila, F; Friedlaender, A; Camerini, A; Christopoulou, A; Cantale, O; De Toma, A; Pizzutilo, P; Jimenez, B; Collazo-Lorduy, A; Calles, A; Baxevanos, P; Linardou, H; Kosmidis, P; Giannarelli, D; Mountzios, G; Addeo, A

Metro, G (corresponding author), Santa Maria della Misericordia Hosp, Dept Med Oncol, Via Dottori 1, I-06156 Perugia, Italy.

Abstract

The authors conducted a multicenter retrospective study on the outcome of programmed death-ligand 1 tumor proportion score >= 50% advanced non-smal......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression >= 50%

科室

工具

服务